Rebecca P A Ellston

发表

Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines.

Stephen Green, J Elizabeth Pease, R. Pauptit, 2003, Bioorganic & medicinal chemistry letters.

Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines.

Stephen Green, J Elizabeth Pease, Russell T Naven, 2003, Bioorganic & medicinal chemistry letters.

Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation.

J. Breed, R. Pauptit, C. Minshull, 2003, Bioorganic & medicinal chemistry letters.

Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores

Stephen S. Taylor, V. L. Johnson, N. Keen, 2003, The Journal of cell biology.

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

S. Barry, S. Ashton, P. Hall, 2016, Science Translational Medicine.

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

Lisa L. Smith, C. Chresta, S. Guichard, 2010, Cancer research.

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.

S. Barry, B. Davies, J. Trapman, 2015, European urology.

Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.

Peter D Smith, J. Kendrew, Rebecca P A Ellston, 2006, Bioorganic & medicinal chemistry letters.

Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.

S. Green, Rebecca P A Ellston, B. Barlaam, 2017, Bioorganic & medicinal chemistry letters.

457 Preclinical pharmacology of AZD5312, a generation 2.5 antisense oligonucletotide targeting the androgen receptor with differentiated activity from enzalutamide

M. Jo, B. Davies, D. Blakey, 2014 .

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

O. Delpuech, S. Green, Á. Avivar-Valderas, 2016, Molecular Cancer Therapeutics.

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

P. Lyne, B. Monia, D. Blakey, 2017, Science Translational Medicine.

Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Edward S. Kim, X. Wang, I. Wistuba, 2013, Clinical Cancer Research.

Abstract 3264: AZD8186: a potent selective inhibitor of PI3Kβ targeting PTEN-deficient tumours dependent on dysregulated PI3Kβ signalling.

S. Barry, S. Green, Rebecca P A Ellston, 2013 .

Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors

S. Barry, O. Delpuech, Á. Avivar-Valderas, 2017, Clinical Cancer Research.

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

S. Barry, Paul D. Smith, E. Harrington, 2014, Molecular Cancer Therapeutics.

Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.

S. Green, Rebecca P A Ellston, B. Barlaam, 2015, Bioorganic & medicinal chemistry letters.